

Bhagwan Yadav

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4072734/publications.pdf>

Version: 2024-02-01

46
papers

2,413
citations

304743
22
h-index

330143
37
g-index

49
all docs

49
docs citations

49
times ranked

4430
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model. Computational and Structural Biotechnology Journal, 2015, 13, 504-513. | 4.1 | 485 |
| 2 | Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. Cancer Discovery, 2013, 3, 1416-1429. | 9.4 | 334 |
| 3 | Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Scientific Reports, 2014, 4, 5193. | 3.3 | 243 |
| 4 | PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Science Translational Medicine, 2018, 10, . | 12.4 | 116 |
| 5 | Aggressive natural killer-cell leukemia-Âmutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nature Communications, 2018, 9, 1567. | 12.8 | 107 |
| 6 | Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica, 2020, 105, 708-720. | 3.5 | 99 |
| 7 | JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-Âinduced protection of AML. Blood, 2017, 130, 789-802. | 1.4 | 90 |
| 8 | Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways. PLoS Computational Biology, 2013, 9, e1003226. | 3.2 | 84 |
| 9 | Obatoclax, Saliphenylhalamide, and Gemcitabine Inhibit Influenza A Virus Infection. Journal of Biological Chemistry, 2012, 287, 35324-35332. | 3.4 | 80 |
| 10 | Consistency in drug response profiling. Nature, 2016, 540, E5-E6. | 27.8 | 76 |
| 11 | Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. European Urology, 2017, 71, 319-327. | 1.9 | 74 |
| 12 | Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer Discovery, 2022, 12, 388-401. | 9.4 | 73 |
| 13 | Breeze: an integrated quality control and data analysis application for high-throughput drug screening. Bioinformatics, 2020, 36, 3602-3604. | 4.1 | 68 |
| 14 | Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells. Molecular Cancer, 2016, 15, 34. | 19.2 | 57 |
| 15 | Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1. Journal of Biological Chemistry, 2020, 295, 4194-4211. | 3.4 | 48 |
| 16 | Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected mice. Cell Death and Disease, 2013, 4, e742-e742. | 6.3 | 41 |
| 17 | Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia. Leukemia, 2019, 33, 1360-1372. | 7.2 | 40 |
| 18 | Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. Oncotarget, 2017, 8, 56338-56350. | 1.8 | 35 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2060-2071. | 4.1 | 33 |
| 20 | Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer. <i>Npj Systems Biology and Applications</i> , 2019, 5, 20. | 3.0 | 32 |
| 21 | Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. <i>Oncotarget</i> , 2017, 8, 97516-97527. | 1.8 | 28 |
| 22 | Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells. <i>Gynecologic Oncology</i> , 2017, 144, 621-630. | 1.4 | 26 |
| 23 | Systematic Mapping of Kinase Addiction Combinations in Breast Cancer Cells by Integrating Drug Sensitivity and Selectivity Profiles. <i>Chemistry and Biology</i> , 2015, 22, 1144-1155. | 6.0 | 22 |
| 24 | Suppression of BRCA1 sensitizes cells to proteasome inhibitors. <i>Cell Death and Disease</i> , 2014, 5, e1580-e1580. | 6.3 | 21 |
| 25 | Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing. <i>Blood Cancer Journal</i> , 2015, 5, e309-e309. | 6.2 | 19 |
| 26 | Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. <i>Oncolimmunology</i> , 2019, 8, e1638210. | 4.6 | 19 |
| 27 | From drug response profiling to target addiction scoring in cancer cell models. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 1255-1264. | 2.4 | 13 |
| 28 | Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature. <i>Frontiers in Immunology</i> , 2020, 11, 578848. | 4.8 | 11 |
| 29 | Integrated Analysis of Drug Sensitivity and Selectivity to Predict Synergistic Drug Combinations and Target Coaddictions in Cancer. <i>Methods in Molecular Biology</i> , 2019, 1888, 205-217. | 0.9 | 7 |
| 30 | KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2780-2784. | 7.2 | 6 |
| 31 | Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia. <i>HemaSphere</i> , 2022, 6, e701. | 2.7 | 4 |
| 32 | High miR-30 Expression Associates with Improved Breast Cancer Patient Survival and Treatment Outcome. <i>Cancers</i> , 2021, 13, 2907. | 3.7 | 3 |
| 33 | Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma. <i>Blood</i> , 2014, 124, 2046-2046. | 1.4 | 3 |
| 34 | Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. <i>Blood</i> , 2017, 130, 854-854. | 1.4 | 1 |
| 35 | High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML. <i>Blood</i> , 2012, 120, 288-288. | 1.4 | 1 |
| 36 | AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines. <i>Blood</i> , 2014, 124, 2163-2163. | 1.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Abstract 5588: Functional drug sensitivity and resistance profiling of AML patient cells defines a disease-specific combination of druggable signal addictions.. , 2013, , . | | 0 |
| 38 | Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies. Blood, 2013, 122, 1668-1668. | 1.4 | 0 |
| 39 | Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. Blood, 2013, 122, 482-482. | 1.4 | 0 |
| 40 | Abstract 5384: Systematic high-throughput drug sensitivity and resistance testing (DSRT) of ovarian cancer cell lines indicates novel therapeutic possibilities with existing and emerging drugs. , 2014, , . | | 0 |
| 41 | Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling. Blood, 2014, 124, 2160-2160. | 1.4 | 0 |
| 42 | Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing. Blood, 2014, 124, 3505-3505. | 1.4 | 0 |
| 43 | Abstract P6-02-01: Identification of subgroups of triple negative breast cancer cells with selective responses to mTOR, CDK, mitotic and proteasome inhibitors. , 2015, , . | | 0 |
| 44 | JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML. Blood, 2015, 126, 867-867. | 1.4 | 0 |
| 45 | Mutational Landscape of Aggressive Natural Killer Cell Leukemia and Drug Sensitivity Profiling Reveal Therapeutic Options in Natural Killer Cell Malignancies. Blood, 2016, 128, 2921-2921. | 1.4 | 0 |
| 46 | Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML. Blood, 2016, 128, 4711-4711. | 1.4 | 0 |